Surgery Partners reaffirms 2021/2022 guidance, appoints David Doherty as CFO

Surgery Partners, Inc.

David Doherty appointed EVP & CFO effective Feb 1, 2022, succeeding Thomas Cowhey who resigns Jan 31, 2022.
Doherty receives $515K base salary, 75% target bonus, $200K restricted stock award, $800K annual equity target.
Company reaffirms 2021 Adjusted EBITDA guidance of $325M-$330M and revenue growth 19%-21% vs 2020.
Completed $185M in three December 2021 acquisitions at ~8.5x 2022E EBITDA; reaffirms 2022 Adj EBITDA min $370M.
Cowhey to remain through Feb 2022; his unvested PSUs and restricted stock vest in March 2022 as agreed.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David T. Doherty

Executive Vice President and Chief Financial Officer

SGRY · Surgery Partners, Inc.

Effective: 2022-02-01
Filed: January 10, 2022, 6:59 PM ET

On January 10, 2022, the Company announced the appointment of David T. Doherty to serve as Executive Vice President and Chief Financial Officer of the Company, effective as of February 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David T. Doherty was appointed as Executive Vice President and Chief Financial Officer at Surgery Partners, Inc..

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On January 10, 2022, the Company announced the appointment of David T. Doherty to serve as Executive Vice President and Chief Financial Officer of the Company, effective as of February 1, 2022.

View on SEC.gov

Surgery Partners, Inc. filing history →

Source: SEC EDGAR

accession 0001638833-22-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.